The Quest for Early Detection in Alzheimer's Disease: What Blood-based Biomarkers & Cognitive Tests
This event is in the past.
9:30 a.m. to 10:30 a.m.
Alzheimer's disease (AD) is the 6th leading cause of death and with an aging population its rate of occurrence is steeply on the rise. To date, we have no cure or effective therapy, in part because by the time individuals exhibit symptoms the underlying damage to the brain is extensive and difficult to treat. Dr. Engeland will discuss the current treatments available to patients and the strong need for earlier detection in individuals who are at high risk for developing AD. Blood-based biomarkers and some new findings in cognitive testing may aid in the detection of this disease.
Dr. Chris Engeland is the Director of Penn State University’s Stress and Immunity Lab. He is an associate professor of Biobehavioral Health. His research focuses on the effects of stress, inflammation, age and sex on cognitive aging, dementia and depression in humans as well as the effects of stress, age and sex on wound healing and inflammation in animals. He is currently the principal investigator for a NIH PO1 study on depression, inflammation, biological age, and cognitive function.